Angelini Pharma – An overview of the US pharma landscape


e-version image

Click HERE to download the PDF

Over the past 10+ years the pharmaceutical Industry has utilized CDMO’s at an increasing level from year to year never seen prior to this period. The reasons are multidimensional involving a combination of new complex molecules for drug therapies such as NASH, antivirals (e.g. Hepatitis and most recently CoVID) as well as the ever expanding Oncology sector, all with small molecules being still dominant.

While biologics continue to grow, and it was thought by many that small molecules would eventually become a small sector of the overall NCE market, but this has not been the case. In the US NDAs for small molecules still account for approximately 70-75% of the total NDA approvals. For example, during 2017-2021 an avera ...